These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

730 related articles for article (PubMed ID: 18657680)

  • 1. Current antiplatelet therapies: benefits and limitations.
    Angiolillo DJ; Guzman LA; Bass TA
    Am Heart J; 2008 Aug; 156(2 Suppl):S3-9. PubMed ID: 18657680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT; Regal RE; Dorsch MP
    Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controversies of oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.
    Rajagopal V; Bhatt DL
    Semin Thromb Hemost; 2004 Dec; 30(6):649-55. PubMed ID: 15630671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes.
    Alagona P
    J Invasive Cardiol; 2010 Jan; 22(1):40-4. PubMed ID: 20048399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet function monitoring in patients with coronary artery disease.
    Gurbel PA; Becker RC; Mann KG; Steinhubl SR; Michelson AD
    J Am Coll Cardiol; 2007 Nov; 50(19):1822-34. PubMed ID: 17980247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variability in responsiveness to oral antiplatelet therapy.
    Angiolillo DJ
    Am J Cardiol; 2009 Feb; 103(3 Suppl):27A-34A. PubMed ID: 19166710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prasugrel: Clinical development and therapeutic application.
    Guerra DR; Tcheng JE
    Adv Ther; 2009 Nov; 26(11):999-1011. PubMed ID: 20020231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet therapy in acute coronary syndromes: the emergency physician's perspective.
    Pollack CV; Hollander JE
    J Emerg Med; 2008 Jul; 35(1):5-13. PubMed ID: 18359601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention?
    Steinhubl S; Berger P
    Am Heart J; 2003 Jun; 145(6):971-8. PubMed ID: 12796751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
    Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA
    J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral antiplatelet therapy for percutaneous coronary revascularization.
    Hamdalla H; Steinhubl SR
    Catheter Cardiovasc Interv; 2007 Apr; 69(5):637-42. PubMed ID: 17351930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of antiplatelet therapy across the spectrum of patients with coronary artery disease.
    Bhatt DL
    Am J Cardiol; 2009 Feb; 103(3 Suppl):11A-19A. PubMed ID: 19166708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.
    Robinson A; Das K; Koshy SK; Das P
    Future Cardiol; 2009 May; 5(3):237-46. PubMed ID: 19450050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: when does the risk outweigh the benefit?
    Collet JP; Montalescot G
    Int J Cardiol; 2009 Mar; 133(1):8-17. PubMed ID: 19187982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond.
    Cohen M
    Catheter Cardiovasc Interv; 2009 Oct; 74(4):579-97. PubMed ID: 19472347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular events.
    Terpening C
    J Am Board Fam Med; 2009; 22(1):51-6. PubMed ID: 19124633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clopidogrel: an updated and comprehensive review.
    Fox KA; Chelliah R
    Expert Opin Drug Metab Toxicol; 2007 Aug; 3(4):621-31. PubMed ID: 17696811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials.
    Mariani M; Mariani G; De Servi S
    Expert Rev Cardiovasc Ther; 2009 Jan; 7(1):17-23. PubMed ID: 19105763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.